Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Quest Diagnostics (DGX) gains in Q2 banking on the acquisition of Med Fusion and ClearPoint.
The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
While the revised American Health Care Act now only needs the Senate's nod, the scenario is getting increasingly challenging for the Medical Device Space.
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.
Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.
Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.
Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.
Investors' pessimism about Envision Healthcare (EVHC) has stemmed from the decline in 2017 earnings guidance, following first-quarter results.
LabCorp's (LH) Covance drug development business has recently opened a companion diagnostics laboratory in Morrisville, North Carolina to expand capabilities in precision medicine field.
Quest Diagnostics (DGX) recently announced agreements to acquire two laboratory businesses in Lewisville, Texas, namely Med Fusion and Clear Point.
Share price of Madison, NJ-based Quest Diagnostics, Inc. (DGX) scaled a new 52-week high of $108.52 on May 16, eventually closing a bit lower at $108.14.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Humana Inc.'s (HUM) first-quarter 2017 operating earnings per share of $2.75 beat the Zacks Consensus Estimate by approximately 8%.
Health insurer Aetna Inc.'s (AET) first-quarter 2017 earnings of $2.71 per share surpassed the Zacks Consensus Estimate of $2.36 and also grew 17% year over year.